araag2/HINT huggingface dataset:
Clinical trial NCT02493712 (phase 2, status: completed)
Conditions: colitis, ulcerative
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: high dose, low dose, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female, age ≥18 and <75 years, suffering from UC for at least 6 months prior
             to screening

          2. Female patients must be postmenopausal, sterile, or have a negative urine pregnancy
             test prior to entering the study and use adequate contraception during the study if of
             childbearing potential.

          3. Diagnosis of active UC with UCDAI ≥4 and ≤10, with endoscopy score of ≥1 in the UCDAI
             mucosal appearance subscore

        Exclusion Criteria:

          1. Patients diagnosed with Crohn's disease, indeterminate colitis, or ischemic colitis

          2. Female patients who are pregnant or breastfeeding

          3. Ulcerative proctitis with ≤15 cm of disease

          4. Patients with infectious colitis as determined by assessment for Clostridium difficile
             (C. difficile) and fecal pathogens at screening or treatment for C. difficile within
             30 days prior to screening

          5. History of or current evidence of toxic megacolon, fulminant colitis (e.g., Lichtiger
             score of ≥10), colonic perforation
Clinical trial NCT02493855 (phase 2, status: completed)
Conditions: chronic hepatitis c, hepatitis c (hcv), hepatitis c genotype 1a
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4, B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2, B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: ombitasvir/abt-450/ritonavir, dasabuvir, ribavirin (rbv)
SMILES: CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          1. Screening laboratory result indicating HCV genotype 1 (GT1) a infection.

          2. Chronic HCV infection.

          3. Subjects must be non-cirrhotic.

          4. Subjects must be able to understand and adhere to the study visit schedule and all
             protocol requirements as well as voluntarily sign and date an institutional review
             board (IRB) approved informed consent.

        Exclusion Criteria:

          1. Women who are pregnant or breastfeeding.

          2. Positive test result for hepatitis B surface antigen (HBsAg) or anti-human
             immunodeficiency virus antibody (HIV Ab) positive immunoassay.

          3. Clinically significant abnormalities or co-morbidities, other than HCV infection, that
             make the subject unsuitable for this study or treatment.

          4. Current enrollment in another interventional clinical study. Previous use of any HCV
             treatments including pegylated interferon (pegIFN), ribavirin, or any direct acting
             antiviral agent, either investigational or approved, for HCV including protease
             inhibitors, nucleoside or non-nucleoside polymerase inhibitors, or nonstructural viral
             protein 5A (NS5A) inhibitors.

          5. History or solid organ transplant.

          6. Screening laboratory analysis that shows abnormal results.
Clinical trial NCT02495623 (phase 2, status: completed)
Conditions: irritable bowel syndrome with constipation (ibs-c)
ICD codes: K59.00, K59.09, K59.01, K59.02, K59.03, K59.04, K58.1
Drugs: syn-010 21 mg, syn-010 42 mg, placebo
SMILES: [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC, [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have IBS-C and have a positive breath CH4 test result (> 10 ppm) at
             Screening.

          -  Subject must meet the modified Rome III criteria for IBS-C.

          -  Subject must have an average abdominal pain intensity score of ≥ 3 (scale 0-10)
             reported at Screening and Baseline.

          -  Subject must have an average of fewer than 3 complete spontaneous bowel movement
             (CSBMs) per week.

          -  Subject must agree to refrain from making any lifestyle changes that may affect IBS-C
             symptoms from the time of Screening to the end of the study.

        Exclusion Criteria:

          -  Subject has taken IBS treatments (prescription or over-the-counter), proton pump
             inhibitors, laxatives, antibiotics.

          -  Subject currently has any structural abnormality of the gastrointestinal (GI) tract or
             a disease or condition that can affect GI motility, or any unexplained and clinically
             significant symptoms such as lower GI bleeding, rectal bleeding, heme-positive stool,
             iron-deficiency anemia, weight loss, or systemic signs of infection.

          -  Subject has been diagnosed with or has a family history of familial adenomatous
             polyposis, hereditary nonpolyposis colorectal cancer, or any other form of familial
             colorectal cancer.

          -  Subject reports loose (mushy) or watery stools (Bristol Stool Form Scale [BSFS] score
             of 6 or 7).
Clinical trial NCT02498652 (phase 2, status: completed)
Conditions: gout
ICD codes: M10.9, M10.08, M10.00, M10.011, M10.012, M10.019, M10.021
Drugs: rdea3170 2.5 mg, allopurinol 300 mg
SMILES: CC(C)(SC1=CC=NC=C1C1=C2C=CC=CC2=C(C=C1)C#N)C(O)=O, O=C1N=CN=C2NNC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is able to understand the study procedures and the risks involved and is
             willing to provide written informed consent before the first study-related activity.

          -  Subject meets one or more criteria for the diagnosis of gout as per the American
             Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary
             Gout.

          -  Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 45
             kg/m2.

          -  Subject has a Screening serum urate level ≥ 8 mg/dL.

          -  Subject is free of any clinically significant disease or medical condition, per the
             Investigator's judgment.

        Exclusion Criteria:

          -  Subject is unable to take colchicine for gout flare prophylaxis.

          -  Subject has a history or suspicion of kidney stones.

          -  Subject has any gastrointestinal disorder that affects motility and/or absorption.

          -  Subject had unstable angina, New York Heart Association class III or IV heart failure,
             ischemic heart disease, stroke, or deep venous thrombosis within 12 months prior to
             Day 1; or subject is currently receiving anticoagulants.

          -  Subject has Screening laboratory parameters that are outside the normal limits and are
             considered clinically significant by the Investigator.

          -  Subject has an estimated creatinine clearance < 60 mL/min calculated by the
             Cockcroft-Gault formula using ideal body weight during the Screening period.

          -  Subject is taking losartan, fenofibrate, guaifenesin, or sodium-glucose linked
             transporter-2 inhibitors; chronic and stable doses are permitted if doses are stable
             for at least 14 days prior to study medication dosing.

          -  Subject is unable or unwilling to comply with the study requirements or has a
             situation or condition that, in the opinion of the Investigator, may interfere with
             participation in the study.
Clinical trial NCT02499120 (phase 2, status: active, not recruiting)
Conditions: squamous cell carcinoma of the head and neck (scchn)
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: palbociclib, cetuximab, placebo
SMILES: [Na+].CC([O-])=O, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Histologically or cytologically confirmed squamous cell carcinoma of the oral cavity,
             oropharynx, hypopharynx or larynx, not amenable for salvage surgery or radiotherapy.

          -  Measurable disease as defined per RECIST v. 1.1. Tumor lesions previously irradiated
             or subjected to other locoregional therapy will only be deemed measureable if disease
             progression at the treated site after completion of therapy is clearly documented.

          -  HPV- negative SCCHN tumor as determined per institutional standard (eg, p16 IHC;
             multiplex nucleic acid sequence based amplification [NASBA] or other polymerase chain
             reaction [PCR]-based assays).

          -  Documented progressive disease according to RECIST v1.1 (Appendix 2) following receipt
             of at least 2 cycles of one platinum-containing chemotherapy regimen administered for
             R/M disease (min. 50 mg/m2 for cisplatin, minimum area under the curve [AUC] > 4 for
             carboplatin).

          -  Availability of a tumor tissue specimen (ie, archived formalin fixed paraffin embedded
             tissue [block preferred, or 15 unstained slides]), which will be used for centralized,
             retrospective biomarker analysis. If archived tumor tissue is not available, then a de
             novo biopsy will be required for patient participation.

        Key Exclusion Criteria:

          -  Prior nasopharyngeal cancer, salivary gland or sinus tumors.

          -  More than one chemotherapeutic regimen given for R/M disease. Prior treatment with
             immunotherapy is allowed.

          -  Known active uncontrolled or symptomatic central nervous system (CNS) metastases,
             carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms,
             cerebral edema, and/or progressive growth. Patients with a history of CNS metastases
             or cord compression are eligible if they have been definitively treated with local
             therapy (eg, radiotherapy, stereotactic surgery) and are clinically stable off
             anticonvulsants and steroids for at least 4 weeks before randomization.

          -  Progressive disease within 3 months after completion of curatively intended treatment
             for locoregionally advanced SCCHN.

          -  Difficulty swallowing capsules.

          -  Prior use of cetuximab in the R/M disease treatment setting (except cetuximab during
             curative radiotherapy)
Clinical trial NCT02504671 (phase 2, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: gsk3196165, mtx, folic acid, placebo
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age >=18 years at the time of signing informed consent.

          -  Meets ACR/EULAR 2010 RA Classification Criteria, with disease duration of >=12 weeks.

          -  Swollen joint count of >=4 (66-joint count) and tender joint count of >=4 (68-joint
             count).

          -  DAS28(CRP) >=3.2.

          -  CRP >=5.0 milligram per litre (mg/L) at screening.

          -  Must have previously received MTX (15-25 mg weekly) for at least 12 weeks before
             screening, with no change in route of administration, with a stable and tolerated dose
             for >=4 weeks prior to Day 1. A stable dose of MTX >=7.5 mg/week is acceptable, if the
             MTX dose has been reduced for reasons of documented intolerance to MTX, e.g. hepatic
             or hematologic toxicity, or per local requirement.

          -  Weight >=45 kilogram (kg).

          -  Male or female subjects are eligible to participate so long as they meet and agree to
             abide by the contraceptive criteria.

          -  Diffusing capacity of the lung for carbon monoxide (DLCO) >=60% predicted; forced
             expiratory volume in 1 second (FEV1) >=70% predicted

          -  No evidence of active or latent infection with Mycobacterium tuberculosis (TB).

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  History of other inflammatory rheumatological or autoimmune disorders, other than
             Sjögren's syndrome secondary to RA.

          -  History of any respiratory disease which (in the opinion of the investigator) would
             compromise subject safety or the ability of the subject to complete the study (e.g.
             significant interstitial lung disease, such as pulmonary fibrosis, chronic obstructive
             pulmonary disease (COPD), moderate-severe asthma, bronchiectasis, previous pulmonary
             alveolar proteinosis [PAP]).

          -  Clinically-significant or unstable (in the opinion of the investigator) persistent
             cough or dyspnea that is unexplained.

          -  Significant unstable or uncontrolled acute or chronic disease which, in the opinion of
             the investigator, could confound the results of the study or put the subject at undue
             risk.

          -  A history of malignancy.

          -  Hereditary or acquired immunodeficiency disorder, including immunoglobulin deficiency.

          -  Current/previous Hepatitis B virus (HBV), Hepatitis C virus (HCV) or human
             immunodeficiency virus (HIV) 1 or 2 infection.
Clinical trial NCT02508649 (phase 2/phase 3, status: terminated)
Conditions: septic shock
ICD codes: T81.12XS, R65.20, R65.21, T81.12XA, T81.12XD
Drugs: selepressin, placebo
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    terminated due to futility
  
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older

          -  Proven or suspected infection

          -  Septic shock defined as hypotension requiring vasopressor treatment despite adequate
             fluid resuscitation

          -  Informed consent obtained in accordance with local regulations

        Exclusion Criteria:

          -  Not possible to initiate trial drug treatment within 12 hours from onset of
             vasopressor treatment for septic shock

          -  Primary cause of hypotension not due to sepsis

          -  Previous severe sepsis with intensive care unit admission within this hospital stay

          -  Known/suspected acute mesenteric ischaemia

          -  Suspicion of concomitant acute coronary syndrome based on clinical symptoms and/or ECG
             during this episode of septic shock

          -  Chronic mechanical ventilation for any reason OR severe chronic obstructive pulmonary
             disease (COPD) requiring either continuous daily oxygen use during the preceding 30
             days or mechanical ventilation (for acute exacerbation of COPD) during the preceding
             30 days

          -  Received bone marrow transplant during the preceding 6 months or chemotherapy during
             the preceding 30 days for lymphoma or leukemia

          -  Known to be pregnant

          -  Decision to limit full care taken before obtaining informed consent

          -  Use of vasopressin in the past 12 hours prior to start of trial drug treatment or use
             of terlipressin within 7 days prior to start of trial drug treatment

          -  Prior enrolment in the trial

          -  Prior use of an investigational medicinal product within the last month OR planned or
             concurrent participation in a clinical trial for any investigational drug or
             investigational device
Clinical trial NCT02510599 (phase 2, status: completed)
Conditions: nonalcoholic steatohepatitis
ICD codes: K75.81
Drugs: solithromycin
SMILES: [H][C@]12N(CCCCN3C=C(N=N3)C3=CC(N)=CC=C3)C(=O)O[C@]1(C)[C@@]([H])(CC)OC(=O)[C@@](C)(F)C(=O)[C@]([H])(C)[C@@]([H])(O[C@]1([H])O[C@]([H])(C)C[C@]([H])(N(C)C)[C@@]1([H])O)[C@@](C)(C[C@@]([H])(C)C(=O)[C@]2([H])C)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic evidence of NASH based on liver biopsy obtained within 180 days

          -  NAS> or = 5

          -  Able to swallow capsules intact

        Exclusion Criteria:

          -  Symptoms of acute liver disease

          -  Cirrhosis on liver biopsy

          -  Positive HIV or Hepatitis tests

          -  Primary Biliary Cirrhosis

          -  Poorly controlled diabetes with HgA1C >8.5%

          -  ALT >4-fold upper limit of normal

          -  QTcF >450 msec

          -  CrCl <40 mL/min
Clinical trial NCT02515942 (phase 2, status: completed)
Conditions: geographic atrophy
ICD codes: K14.1
Drugs: clg561, lfg316, sham injection
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Sign written informed consent form;

          -  Geographic atrophy in both eyes;

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Pregnant or lactating women and women of child-bearing potential;

          -  Any medical condition (systemic or ophthalmic) that may preclude the safe
             administration of test article or safe participation in this study;

          -  Any contraindications or hypersensitivities to any component of the LFG316 or CLG561
             solution;

          -  Any contraindications to IVT injections;

          -  Ocular surgery in either eye within 90 days of screening;

          -  Uncontrolled ocular hypertension or glaucoma in the study eye;

          -  Other protocol-specified exclusion criteria may apply.
Clinical trial NCT02525302 (phase 2, status: terminated)
Conditions: duchenne muscular dystrophy
ICD codes: G71.01
Drugs: ht-100
SMILES: [H][C@]1(O)CCCN[C@]1([H])CC(=O)CN1C=NC2=C(C=C(Cl)C(Br)=C2)C1=O
Reason stopped: 
    dosing stopped
  
Eligibility criteria:

        Inclusion Criteria:

          1. Completed both previous studies HALO-DMD-01 and HALO-DMD-02

          2. Ability to provide written informed consent

          3. Ability to understand and follow site and protocol instruction for the entire duration
             of the study

        Exclusion Criteria:

        Answering yes to any of the following make the subject NOT eligible to participate in the
        study.

          1. Clinically significant major disease not related to DMD that would make it not safe to
             be in the study or affect ability to follow the protocol

          2. History of severe allergic or anaphylactic reactions

          3. Recent report of drug/alcohol abuse
Clinical trial NCT02527343 (phase 2/phase 3, status: active, not recruiting)
Conditions: familial partial lipodystrophy
ICD codes: E88.1
Drugs: volanesorsen, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must give written informed consent to participate in the study (signed and dated) and
             any authorizations required by law

          -  Clinical diagnosis of FPL plus diagnosis of type 2 diabetes mellitus,
             hypertriglyceridemia, and fatty liver

               -  Diagnosis of FPL is based on deficiency of subcutaneous body fat in a partial
                  fashion assessed by physical examination and low skinfold thickness in anterior
                  thigh by caliper measurement: men (≤ 10 mm) and women (≤ 22 mm), and at least 1
                  of the following:

                    1. Genetic diagnosis of FPL OR

                    2. Family history of FPL or of similar abnormal fat distribution plus 1 Minor
                       Criteria OR

                    3. In the absence of FPL-associated genetic variant or family history, 2 Minor
                       Criteria and BMI< 35 kg/m2

               -  Diabetes not well controlled on antidiabetic therapy with HbA1c ≥ 7% to ≤ 12% at
                  Screening

               -  Hypertriglyceridemia with Fasting TG levels ≥ 500 mg/dL (≥ 5.7 mmol/L) at
                  Screening and Qualification visit, or Fasting TG levels ≥ 200 (≥ 2.26 mmol/L) at
                  both Screening and Qualification Visits for patients who meet the genetic or
                  family history criteria

               -  Presence of hepatosteatosis (fatty liver), as evidenced by a Screening MRI
                  indicating a hepatic fat fraction (HFF) ≥ 6.4%.

        Exclusion Criteria:

          -  A diagnosis of generalized lipodystrophy

          -  A diagnosis of acquired partial lipodystrophy

          -  Acute pancreatitis within 4 weeks of Screening

          -  History within 6 months of Screening of acute or unstable cardiac condition

          -  LDL-C > 130 mg/dL on maximal tolerated statin therapy

          -  Platelet count < lower limit of normal (LLN)

          -  Treatment with metreleptin within the last 3 months prior to Screening